H1N1 infection - Pipeline Insight, 2024

This “H1N1 infection - Pipeline Insight, 2024,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in H1N1 infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

H1N1 infection Understanding

H1N1 infection: Overview

H1N1 Swine flu is a subtype of influenza A virus (a communicable viral disease), which causes upper, and potentially, lower respiratory tract infections in the host it infects, resulting in symptoms such as nasal secretions, chills, fever, decreased appetite, and possibly lower respiratory tract disease. H1N1 swine influenza is a common infection in pigs worldwide, and that is why it is also known as swine flu. H1N1 swine flu leads to respiratory disease that can potentially infect the respiratory tract of pigs. Sometimes, people who are closely associated with pigs or in the proximity of pigs have developed swine flu (zoonotic swine flu). Swine influenza viruses can potentially cause infections in humans if antigenic characteristics of the virus change through reassortment. When this happens, transmission from person-to-person is usually inefficient. Influenza A pandemics such as the ones in 1918 and 2009 can occur if the transmission from person-to-person becomes efficient. The initial and best step in management should be to prevent swine flu. Specifically, with the prevention of swine flu in swine, prevention of transmission of swine flu from swine-to-humans, and prevention of human-to-human spread. The management for infected patients depends on the severity of symptoms of influenza, mild to moderate influenza can be treated at home with rest, oral hydration and symptomatic treatment with antipyretics like paracetamol, antihistaminic for nasal congestion and rhinitis and NSAIDS or Paracetamol for headaches and body aches.

H1N1 infection - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the H1N1 infection pipeline landscape is provided which includes the disease overview and H1N1 infection treatment guidelines. The assessment part of the report embraces, in depth H1N1 infection commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, H1N1 infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence H1N1 infection R&D. The therapies under development are focused on novel approaches to treat/improve H1N1 infection.

H1N1 infection Emerging Drugs Chapters

This segment of the H1N1 infection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

H1N1 infection Emerging Drugs

SAB 176: SAB BiotherapeuticsSAB-176 is a multivalent, broadly neutralizing fully-human polyclonal antibody therapeutic candidate in development for the treatment or prevention of severe influenza. The novel, specifically-targeted therapeutic leverages the natural human biological immune response to specifically bind to Type A and Type B influenza viruses. Like vaccines, it can be modified to address annual strain changes, when needed, to maintain broader coverage as the flu virus mutates. Preclinical data suggests that SAB-176 offers broad protection against diverse influenza strains. The drug is currently in Phase II stage of clinical trial evaluation to treat Influenza A H1N1.

CodaVax-H1N1: CodagenixA live-attenuated influenza vaccine, CodaVax-H1N1, is being developed by Codagenix. The vaccine enables presentation of conserved antigens of the wild-type virus, demonstrating universal potential in primate models and thus the potential to provide multi-season protection when developed into its final quadrivalent formulation. Currently, it is in Phase I stage of clinical trial evaluation to treat H1N1 infection.

H1N1 infection: Therapeutic Assessment

This segment of the report provides insights about the different H1N1 infection drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in H1N1 infection

There are approx. 20+ key companies which are developing the therapies for H1N1 infection. The companies which have their H1N1 infection drug candidates in the most advanced stage, i.e. phase II include, SAB Biotherapeutics.

Phases

This report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

H1N1 infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

H1N1 infection: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses H1N1 infection therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging H1N1 infection drugs.

H1N1 infection Report Insights

• H1N1 infection Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

H1N1 infection Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing H1N1 infection drugs?
• How many H1N1 infection drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of H1N1 infection?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the H1N1 infection therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for H1N1 infection and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• SAB Biotherapeutics
• Codagenix, Inc
• Cocrystal Pharma
• Collaborations Pharmaceuticals
• Vaxart, Inc.
• Adimmune Corporation
• Model Medicines
• NanoViricides
• Ansun Biopharma
• Immune Therapeutics, Inc.
• Ena Respiratory
• EpiVax, Inc.
• Mayly Life Sciences
• Recce Pharmaceuticals
• Vivaldi Biosciences
• Sonnet BioTherapeutics

Key Products

• SAB 176
• CODA-VAX H1N1
• CC-42344
• MDL-001
• DAS-181
• INNA-051
• RECCE 327
• DeltaFLU
• SON-1010

This product will be delivered within 1-3 business days.